** Johnson & Johnson JNJ.N halved its expectations for costs this year related to new tariffs and raised full-year sales and profit forecast on Wednesday after a strong quarter for its flagship cancer drug Darzalex and cardiovascular devices
INNOVATIVE MEDICINES SEGMENT TO LEAD GAINS
** J.P.Morgan ("neutral," PT: $185) says JNJ's underlying business is well positioned and capable of generating over 5% revenue growth with the innovative medicines segment and medtech portfolio supporting growth
** Morningstar (fair value: $172) says on potential pharmaceutical tariffs, JNJ is in a good position with most US-bound products already made in the U.S.
** TD Cowen ("buy," PT: $185) notes JNJ has numerous milestones ahead in the innovation medicine pipeline including TAR-200 for bladder cancer that is set to be commercialized later this year
** Leerink Partners ("market perform," PT: $171) says TAR-200 is well positioned to gain significant market share, aiding co's growth prospects
(Reporting by Kanchana Chakravarty in Bengaluru)
((Kanchana.Chakravarty@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。